Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Otsuka to Pay $865 Million For Europe and China Rights to Akebia's Anemia Treatment

publication date: May 12, 2017
Japan's Otsuka Pharma signed a $865 million deal to add non-US rights (including China) for a late-stage anemia drug from Boston's Akebia Therapeutics. Late in 2016, Otsuka entered a $1 billion agreement for US rights to vadadustat, an oral hypoxia-inducible factor stabilizer. The latest deal adds rights in Europe, China, Russia, Canada, Australia and the Middle East. Akebia will receive $73 million upfront and up to $792 million in development funding and milestone payments for the non-US rights. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital